Biotech Values

[DewDiligence]

RVNC—Why the big jump in [spending] the last three quarters of the year?

From today’s CC (#msg-131213134):

We expect to report results from our SAKURA-1 & -2 Phase 3 pivotal trials in glabellar lines, the 24-week Phase 2 results for cervical dystonia, and topline Phase 2 results for our new indication, plantar fasciitis, all within the next seven months… Before year-end, we expect to release additional results showing the quantitative and qualitative benefits of RT002 in both aesthetic and therapeutic indications.

…we are focused on pre-BLA and pre-commercial activities to ensure a successful approval and launch of RT002 Injectable. We have been hiring experienced, industry veterans in key positions and completing key branding and awareness projects focused on improving the consumer experience and practice economics.

Further to the above, expanding the plantar fasciittis trial to three sites, enrolling the open-label safety study in glabellar lines, and analyzing the data from SAKURA-1/2 will boost the R&D spending rate above the $19.4M quarterly amount in 1Q17.